Business
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI
Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, inclu...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI\n\n\n\n\n Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI\n \n\n At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoE\n \n\n Also, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month results\n \n\n Additional long-term data to be released with higher doses in Q3 2025\n \n\n Eupraxia to host webinar with guest, Dr. Evan Dellon, to discuss data from RESOLVE trial on Friday, May 9\n \n th\n \n at 9:00am ET (Register\n \n here\n \n )\n \n\n\n\n VICTORIA, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced positive treatment outcomes from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (\"EoE\"). Most notably, nine-month data was disclosed for the first time demonstrating that all three patients dosed at 48mg of EP-104GI experienced sustained or improved treatment outcomes after nine months of therapy.\n \n\n “EoE is a chronic medical condition and novel treatment options are needed to effectively manage the long-term tissue inflammation and other associated symptoms of EoE,” said Dr. Evan S. Dellon, MD, MPH (University of North Carolina School of Medicine) and Chairman of the Company's Gastrointestinal Clinical Advisory Board. “The durability in symptom reduction coupled with the prolonged improvement in tissue health from the ongoing RESOLVE trial suggest that EP-104GI could be exerting a tissue remodeling effect on the esophagus. Based on these encouraging results, I look forward to EP-104GI continuing to advance in the clinic, as ...